The Medical University of South Carolina (MUSC) Hollings Cancer Center has attained National Cancer Institute (NCI) designation, a distinction held by only 63 other cancer centers in the U.S. The Hollings Cancer Center (HCC) is the only institution in South Carolina with this prestigious status.
Being named one of the top cancer research centers in the country signals that MUSC/HCC researchers and physicians are leaders in discovering, developing, and delivering cutting-edge treatments based on laboratory research to patients in South Carolina and beyond. The immediate benefit to patients is increased access to early clinical trials offering promising new treatments.
NCI designation is accompanied by more than $7 million in funding to sustain and grow research efforts at MUSC. The NCI awarded designation to HCC based on its outstanding facilities, commitment to research, leadership, and vision.
NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate diverse research approaches that focus on cancer. They play a vital role in advancing the goal of reducing morbidity and mortality from cancer through increased clinical trials that offer patients new drugs and treatment protocols that would be unavailable to them otherwise.
Designation also holds the potential to spur South Carolina’s economy by attracting public and private funding for new endeavors.